Home

Gas Lines and Inflation…Is This The 80’s?

This past week saw yet another ugly market for micro-caps as the whole investment community seems to be increasingly worried about inflation and interest...

TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

TW's Take: better than expected data leading to TFF increasing the target sales for TAC to over $1B is a positive development, especially as...

Opportunity Knocks, Amryt Smartly Acquires Chiasma

The pandemic-inspired rally of 2020 was an unexpected surprise for many companies, particularly those in biotech, which soared last year. The access to capital,...

Summit Wireless Technologies Posts 181% Q1 2021 Revenue Increase and Guides for 250+% Q2...

TW's Take: business continues to accelerate at WISA. It appears the long-awaited inflection point has been reached and sales are expected to continue growing...

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic...

TW's Take: Cosibelimab has the potential to be a very big drug in the PD-(L)1 space with best in class safety and better pricing...

Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North...

TW's Take: This drug is a good fit for FBIO and potentially a massive home run if efficacy can be shown in Chronic Kidney...

LexaGene Expands Its Sales Team

TW's Take: we are encouraged to see the Company rapidly expanding their sales team. Vet diagnostics is easily a big enough industry to drive...

The Beatings Will Continue Until Morale Improves…

Okay, I was early. I admit it. But, unless growth stocks never rally again, biotech in particular, I'm 100% convinced that buying at these...

OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie

TW's Take: enough progress to lead to the creation of a new company focused on developing these therapeutics is a positive development. This is...

INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update

TW's Take: INmune continues to make solid progress on all fronts. The rest of 2021 should have some exciting catalysts with Quellor data, Xpro...

Amryt Reports Record Q1 2021 Financial and Operating Results

TW's Take: nice to see the guidance increased and it's obvious that the core business is going very well at Amryt, but the key...

Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and...

TW's Take: we have been expecting Amryt to make an acquisition and this one is exciting. The prospects for MYCAPSSA are quite strong and...

Lantern Shines During Biotech Blackout

Biotech stocks continue to take it on the chin. This is the result of an overall shift from growth to value in the market...

Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights

DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform...

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence...

TW's Take: this is very exciting news for Lantern as it is the first time they have licensed their RADR platform for third party...

Alpha-Bet Soup

There are times when stock picking isn't the most important part of your investment strategy. When all that matters is being in the right...

Trading Blog, April 30, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

Trade Alert, April 29th, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

QUEST® PROGANICS™ PROVIDES A TRANSFORMATIVE STEP FORWARD IN ORGANICS RECYCLING

TW's Take: we continue to believe that Quest represents a differentiated offering in the traditional business of waste disposal. In a world increasingly focused...

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion...

TW's Take: the rapid growth of datapoints on their A.I. platform is cementing Lantern (LTRN) as a leader in this field. A.I. is changing...

Become a TW Research Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $500 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.